Calls Now Open
2022 ADDF-Harrington and 2023 Harrington UK Rare Disease Programs
Entry of the SARS-CoV-2 coronavirus, which causes COVID-19, requires a host serine protease called TMPRSS2. Camostat mesylate, an orally available serine protease inhibitor, inhibits TMPRSS2, supporting clinical trials to investigate its use in COVID-19.
"The use of innovative modeling by Harrington gave us new insights into how to use Camostat clinically."
- Donald Stanski, MD, Harrington Discovery Institute
Advisor, Therapeutics Development Center
"Our team at Harrington Discovery Institute has stimulated deep, rigorous and invaluable thinking about the development of our drug."
- Joseph Vinetz, MD, FACP, FIDSA, FASTMH, BS
Infectious Disease, Virology
2020 Harrington Award for Coronavirus